Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia

We tested the possibility that pravastatin, a competitive inhibitor of hepatic hydroxymethyl glutaryl coenzyme A (HMG CoA) reductase, would alter cholesterol saturation of gallbladder bile by decreasing its cholesterol saturation index and/or degree of fatty acyl chain unsaturation in lecithin. Eigh...

Full description

Saved in:
Bibliographic Details
Published in:Metabolism, clinical and experimental clinical and experimental, 1995-11, Vol.44 (11), p.1410-1412
Main Authors: Tazuma, Susumu, Takizawa, Itsuo, Kunita, Tetsuro, Mizuno, Toshiyuki, Watanabe, Tetsuhiko, Teramen, Kazushi, Horikawa, Kazuhiko, Ochi, Hidenori, Yamashita, Yoshifumi, Aihara, Naoki, Sasaki, Masatoshi, Hirano, Naomichi, Miura, Hiroyuki, Hatsushika, Sumie, Ohya, Toshihide, Kajiyama, Goro, Itoh, Katsuhide
Format: Article
Language:English
Subjects:
Adult
Aged
Anticholesteremic Agents - pharmacology
Anticholesteremic Agents - therapeutic use
Bile - chemistry
Bile - metabolism
Bile Acids and Salts - analysis
Bile Acids and Salts - metabolism
Biological and medical sciences
Ceruletide - pharmacology
Cholesterol - blood
Cholesterol - metabolism
Disorders of blood lipids. Hyperlipoproteinemia
Dose-Response Relationship, Drug
Fatty Acids - analysis
Female
Gastrointestinal Agents - pharmacology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemias - drug therapy
Hyperlipoproteinemias - metabolism
Lipid Metabolism
Lipids - analysis
Lipids - blood
Male
Medical sciences
Metabolic diseases
Middle Aged
Phosphatidylcholines - analysis
Pravastatin - pharmacology
Pravastatin - therapeutic use
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We tested the possibility that pravastatin, a competitive inhibitor of hepatic hydroxymethyl glutaryl coenzyme A (HMG CoA) reductase, would alter cholesterol saturation of gallbladder bile by decreasing its cholesterol saturation index and/or degree of fatty acyl chain unsaturation in lecithin. Eighteen patients with type IIa hyperlipoproteinemia were treated with pravastatin 10 mg/d for 12 months. Gallbladder bile samples were aspirated with a duodenal tube by stimulating gallbladder contraction with intramuscular administration of cerulein before and after treatment. Serum cholesterol level was significantly reduced by 20% after 3 months, and this level was maintained after 12 months. In contrast, the cholesterol saturation index of gallbladder bile was not altered after 3 months (1.52 ± 0.20 v 1.70 ± 0.24), but it decreased significantly after 12 months (0.95 ± 0.11, P < .01). The degree of fatty acyl chain unsaturation tended to decrease, although this was not statistically significant except for the decrease in molar percent of linoleate after 3 months. These findings suggest that long-term treatment with an inhibitor of HMG CoA reductase improves bile lithogenicity even at a comparatively low dose, and can decrease the incidence and complications of cholesterol gallstones.
ISSN:0026-0495
1532-8600
DOI:10.1016/0026-0495(95)90138-8